MVT-1401-2401 Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Study HIC#:2000035119
- Last Updated:03/19/2024
MVT-1401-2401 study wants to learn more about the safety and effectiveness of an investigational drug called batoclimab to see if it could help CIDP patients manage their symptoms. Batoclimab is an investigational drug, which means it has not been approved by any regulatory health agency for the treatment of CIDP. It is only available to people with active CIDP in research studies like the study referenced above. The results of this study will help doctors and researchers better understand how batoclimab may affect symptoms such as muscle weakness, and the ability to perform daily activities, which could improve the quality of life for CIDP patients.
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Erika Renkl
- Phone Number: 1-475-254-9169
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
MVT-1401-2401 study wants to learn more about the safety and effectiveness of an investigational drug called batoclimab to see if it could help CIDP patients manage their symptoms. Batoclimab is an investigational drug, which means it has not been approved by any regulatory health agency for the treatment of CIDP. It is only available to people with active CIDP in research studies like the study referenced above. The results of this study will help doctors and researchers better understand how batoclimab may affect symptoms such as muscle weakness, and the ability to perform daily activities, which could improve the quality of life for CIDP patients.
Eligibility Criteria
Inclusion Criteria:
- 8 years of age or older
- Have been diagnosed with CIDP
- Have been treated or are currently being treated with medication for CIDP
